Bolar and experimental use exemptions in the EU: how the landscape has changed for generic and biotech drug makers
This article was originally published in SRA
Executive Summary
Manuel Campolini and Ignace Vernimme discuss the regulatory developments relating to the Bolar exemption and consider what lies ahead.